High-dose therapy with stem-cell transplantation in the malignant lymphomas

Jane N. Winter*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

High-dose therapy with hematopoietic progenitor-cell transplantation plays a key role in the treatment of Hodgkin's disease and the non-Hodgkin's lymphomas. First and foremost, transplantation is used as a salvage treatment for those who relapse or do not achieve a complete remission with first-line chemotherapy. Carefully selected patients with poor prognostic features may benefit from the incorporation of high-dose therapy and transplant into their initial treatment programs. Despite a myriad of trials, many pivotal questions regarding the appropriate application of high-dose therapy with transplantation to the lymphoid malignancies remain unsettled, including the role of allogeneic transplantation and the optimal timing of transplant for patients with poor prognostic indicators. Phase III studies are required to address these issues; these trials will demand the active commitment of concerned transplanters and referring hematologists and oncologists. Although autologous transplantation has been the preferred approach for the majority of patient subgroups, new approaches to allogeneic transplantation that have diminished toxicity may pave the way for a greater role for allogeneic grafting in the lymphoid diseases.

Original languageEnglish (US)
Pages (from-to)1635-1645
Number of pages11
JournalONCOLOGY
Volume13
Issue number12
StatePublished - Dec 1 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-dose therapy with stem-cell transplantation in the malignant lymphomas'. Together they form a unique fingerprint.

Cite this